As the Medicine Maker states in its Power List, “2020 has proven to be a challenging year for humanity,” but at Biovault we are so pleased to be rising to the challenge with our collaborator from University College London’s Biochemical Engineering Department, Associate Professor Qasim Rafiq.
Qasim was “humbled and honoured to be named as one of the top 20 advanced therapy medicine makers” in the recently published list which includes “giants within the field”. Here at Biovault we are not surprised that Qasim was part of this esteemed group, as his energy, enthusiasm and commitment to the advancement of cell and gene therapies are the reasons we have chosen to collaborate with him on two research projects using stem cells from the umbilical cord as we look to collectively expedite patient access to these transformative therapies.
As the Associate for a Knowledge Transfer Partnership between Biovault and UCL looking at the expansion of Mesenchymal Stem Cells from Umbilical Cord Tissue, Dr Ivano Colao sums Qasim up perfectly, “Equally ambitious and humble, Qasim brings the best out of himself and his students to drive and serve the greater field of regenerative medicine manufacturing. An endearing colleague, a fantastic mentor and a considerate friend.”
You can read more about Qasim’s achievement here.
Qasim Rafiq, Associate Professor in Cell and Gene Therapy Bioprocess Engineering at University College London
BSc (Hons) Microbiology
Biovault Family CEO, Kate Sneddon, joined Biovault in July 2009 and became Chief Executive Officer in 2016. As health industry professional her experience includes working as a microbiologist and leader at GSK for over 10 years. Her expertise in cord blood banking has been recognised in her awards, features in Parliamentary Review and Parents Guide to Cord Blood, as well as contributions to research with UCL and others.